News >

Future AML Advancements Include Next-Generation Targeted Therapies

Caroline Seymour
Published: Thursday, Sep 27, 2018

Jay Yang, MD

Jay Yang, MD
The treatment paradigm of acute myeloid leukemia (AML) has seen 5 FDA approvals in the past 1.5 years, but could be strengthened by novel second-generation FLT3 inhibitors as well as BCL-2 inhibitors, explained Jay Yang, MD.

“It has been really exciting and refreshing as a leukemia physician,” said Yang. “It's always good to have new and better therapies that give us more options for our patients.”

... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Publication Bottom Border
Border Publication